Search - tctmd.com

Displaying 1 - 20 of 54

Sort: Relevancy | Date

Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD

News Conference News AHA 2025

Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD

November 13, 2025

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

News Conference News ESC 2025

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

September 01, 2025

No Benefit to Routine CT Angiography After Left Main PCI: PULSE

News Conference News ESC 2025

No Benefit to Routine CT Angiography After Left Main PCI: PULSE

Michael O'Riordan

August 31, 2025

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

News Conference News ESC 2025

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

Michael O'Riordan

August 30, 2025

JACC Dedicates Issue to Deep Dive on Latest ACS Guidelines

News Daily News

JACC Dedicates Issue to Deep Dive on Latest ACS Guidelines

June 06, 2025

AHA/ACC Issue New Performance, Quality Measures for Chronic Coronary Disease

News Daily News

AHA/ACC Issue New Performance, Quality Measures for Chronic Coronary Disease

May 06, 2025

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

News Daily News

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

Michael O'Riordan

March 26, 2025

Invasive Testing Safely Diagnoses Microvascular Dysfunction in ANOCA

News Daily News

Invasive Testing Safely Diagnoses Microvascular Dysfunction in ANOCA

Michael O'Riordan

February 24, 2025

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

News Conference News TCT 2024

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Michael O'Riordan

October 29, 2024

Debating a PCI-First Strategy in Stable CAD: ORBITA-2 vs the Unconvinced

News Daily News

Debating a PCI-First Strategy in Stable CAD: ORBITA-2 vs the Unconvinced

Michael O'Riordan

September 20, 2024

ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions

News Conference News ESC 2024

ESC’s 2024 CCS Guidelines Embrace New Data, Smooth Old Tensions

Michael O'Riordan

September 17, 2024

More Support for Ticagrelor Monotherapy After PCI, Especially in ACS

News Conference News ESC 2024

More Support for Ticagrelor Monotherapy After PCI, Especially in ACS

Yael L. Maxwell

September 10, 2024

Obstructive CAD Can Be Left Alone Before TAVI, Observational Data Suggest

News Daily News

Obstructive CAD Can Be Left Alone Before TAVI, Observational Data Suggest

Michael O'Riordan

January 30, 2024

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

News Conference News TCT 2023

Ultrathin Stent Holds Its Own in High-Bleeding-Risk Patients: COMPARE 60/80

Michael O'Riordan

November 01, 2023

More Angina Relief With Complete Revascularization in Stable CAD: ISCHEMIA

News Daily News

More Angina Relief With Complete Revascularization in Stable CAD: ISCHEMIA

Michael O'Riordan

July 18, 2023

Meta-analysis Finds No Excess Mortality Risk With Coronary Revascularization

News Conference News EuroPCR 2023

Meta-analysis Finds No Excess Mortality Risk With Coronary Revascularization

Michael O'Riordan

May 19, 2023

P2Y12 Inhibitors Top Aspirin Following Post-PCI DAPT: Network Meta-analysis

News Daily News

P2Y12 Inhibitors Top Aspirin Following Post-PCI DAPT: Network Meta-analysis

November 21, 2022

Single-Center Study Offers Insights for Ticagrelor vs Prasugrel in Chronic CAD

News Daily News

Single-Center Study Offers Insights for Ticagrelor vs Prasugrel in Chronic CAD

Yael L. Maxwell

November 21, 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

News Conference News ESC 2022

CV Care Around Noncardiac Surgery: New ESC Guidelines

Michael O'Riordan

September 07, 2022

P2Y12 Inhibitors Top Aspirin for Long-term Secondary Prevention: PANTHER

News Conference News ESC 2022

P2Y12 Inhibitors Top Aspirin for Long-term Secondary Prevention: PANTHER

August 29, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.